Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NISHANT GUPTA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1487848875
CMS profile
1060543
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$109.56

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $109.56 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Biosense Webster, Inc. $109.56 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NISHANT GUPTA

NPI 1487848875 · CMS profile ID 1060543

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $109.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biosense Webster, Inc. $109.5601/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718878983 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $411.88 3
PY2020 $109.56 1
PY2021 $2.50 1
PY2022 $338.12 1
PY2023 $12,022.52 6
PY2025 $740.51 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $566,381.76 128
PY2024 Principal investigator $319,780.15 66
PY2023 Principal investigator $287,438.24 47
PY2022 Principal investigator $204,112.69 28
PY2021 Principal investigator $29,775.29 8
PY2020 Principal investigator $82,388.01 22
PY2019 Principal investigator $40,600.47 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

128 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $1,641.60 12/24/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390779
Principal investigator 1 United Therapeutics Corporation $10,245.15 12/24/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390803
Principal investigator 1 United Therapeutics Corporation $1,500.00 12/24/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390879
Principal investigator 1 United Therapeutics Corporation $1,641.60 12/24/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390881
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,100.00 12/12/2025 Non-covered Recipient Entity
University of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806971
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653096
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653098
Principal investigator 1 United Therapeutics Corporation $120.40 12/01/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390805
Principal investigator 1 United Therapeutics Corporation $202.50 12/01/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390809
Principal investigator 1 United Therapeutics Corporation $1,080.00 12/01/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390813
Principal investigator 1 United Therapeutics Corporation $1,649.70 12/01/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390815
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $255.60 11/30/2025 Non-covered Recipient Entity
University Of Cincinnati
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220794419
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $78.60 11/30/2025 Non-covered Recipient Entity
University Of Cincinnati
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220794421
Principal investigator 1 United Therapeutics Corporation $1,468.80 11/26/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390775
Principal investigator 1 United Therapeutics Corporation $1,586.25 11/26/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390777
Principal investigator 1 United Therapeutics Corporation $1,468.80 11/26/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390877
Principal investigator 1 United Therapeutics Corporation $3,329.10 11/26/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390893
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,591.00 11/25/2025 Non-covered Recipient Entity
University of Cincinnati
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806989
Principal investigator 1 United Therapeutics Corporation $3,090.15 11/19/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390821
Principal investigator 1 United Therapeutics Corporation $648.00 11/12/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390767
Principal investigator 1 United Therapeutics Corporation $1,080.00 11/12/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390771
Principal investigator 1 United Therapeutics Corporation $4,838.40 11/12/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390799
Principal investigator 1 United Therapeutics Corporation $4,838.40 11/12/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390901
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $575.00 11/05/2025 Non-covered Recipient Entity
University Of Cincinnati
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220794417
Principal investigator 1 United Therapeutics Corporation $24,889.95 11/03/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390831
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653092
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653094
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,534.30 10/27/2025 Non-covered Recipient Entity
University of Cincinnati
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806987
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653088
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653090
Principal investigator 1 United Therapeutics Corporation $3,996.00 09/10/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390793
Principal investigator 1 United Therapeutics Corporation $3,226.50 09/05/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390823
Principal investigator 1 United Therapeutics Corporation $3,645.00 09/05/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390825
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653082
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653084
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,516.00 08/28/2025 Non-covered Recipient Entity
University of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806969
Principal investigator 1 United Therapeutics Corporation $1,998.00 08/27/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390783
Principal investigator 1 United Therapeutics Corporation $3,324.00 08/27/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390791
Principal investigator 1 United Therapeutics Corporation $4,671.00 08/27/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390897
Principal investigator 1 United Therapeutics Corporation $278.86 08/13/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390871
Principal investigator 1 United Therapeutics Corporation $4,295.10 08/13/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390895
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,010.00 08/06/2025 Non-covered Recipient Entity
University Of Cincinnati
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220794415
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653078
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653080
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,500.00 08/01/2025 Non-covered Recipient Entity
University of Cincinnati
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806985
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 07/28/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653086
Principal investigator 1 United Therapeutics Corporation $1,998.00 07/23/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390781
Principal investigator 1 United Therapeutics Corporation $6,281.55 07/23/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390827
Principal investigator 1 United Therapeutics Corporation $202.50 07/18/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390807
Principal investigator 1 United Therapeutics Corporation $1,080.00 07/18/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390811
Principal investigator 1 United Therapeutics Corporation $13,000.00 07/18/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390829
Principal investigator 1 United Therapeutics Corporation $3,110.40 07/08/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390789
Principal investigator 1 United Therapeutics Corporation $3,110.40 07/08/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390891
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653074
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653076
Principal investigator 1 United Therapeutics Corporation $4,097.25 06/25/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390795
Principal investigator 1 United Therapeutics Corporation $1,748.25 06/25/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390883
Principal investigator 1 United Therapeutics Corporation $4,781.10 06/25/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390899
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,277.55 06/18/2025 Non-covered Recipient Entity
University of Cincinnati
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806981
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,940.00 06/18/2025 Non-covered Recipient Entity
University of Cincinnati
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806983
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,867.75 06/16/2025 Non-covered Recipient Entity
University of Cincinnati
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806979
Principal investigator 1 United Therapeutics Corporation $2,592.00 06/11/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390785
Principal investigator 1 United Therapeutics Corporation $2,592.00 06/11/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390885
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,800.00 06/09/2025 Non-covered Recipient Entity
University of Cincinnati
sGC activator in SSc patients No dispute reported 06/30/2026 1220806973
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,998.00 06/04/2025 Non-covered Recipient Entity
University Of Cincinnati
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220794413
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653062
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653064
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 05/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653066
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653068
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 05/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653070
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 05/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653072
Principal investigator 1 United Therapeutics Corporation $4,664.25 05/21/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390797
Principal investigator 1 United Therapeutics Corporation $5,895.45 05/21/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390903
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,134.00 05/09/2025 Non-covered Recipient Entity
University of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806967
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $163,717.65 05/08/2025 Non-covered Recipient Entity
University Of Cincinnati College Of Medicine
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1235992643
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,131.90 05/07/2025 Non-covered Recipient Entity
University of Cincinnati
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806977
Principal investigator 1 United Therapeutics Corporation $1,468.80 05/07/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390875
Principal investigator 1 United Therapeutics Corporation $2,870.10 05/07/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390887
Principal investigator 1 United Therapeutics Corporation $2,870.10 05/07/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390889
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14.00 05/02/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220794403
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653058
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653060
Principal investigator 1 United Therapeutics Corporation $1,468.80 04/23/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390773
Principal investigator 1 United Therapeutics Corporation $5,744.25 04/23/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390801
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $119,480.00 04/10/2025 Non-covered Recipient Entity
University Of Cincinnati College Of Medicine
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1235992645
Principal investigator 1 United Therapeutics Corporation $864.00 04/09/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390769
Principal investigator 1 United Therapeutics Corporation $3,078.00 04/09/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390787
Principal investigator 1 United Therapeutics Corporation $864.00 04/09/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390873
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.40 04/01/2025 Non-covered Recipient Entity
University Of Cincinnati
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220794409
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $52.40 04/01/2025 Non-covered Recipient Entity
University Of Cincinnati
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220794411
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653016
Principal investigator 1 Boehringer Ingelheim International GmbH $28.04 03/25/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653018
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 03/25/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653020
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 03/25/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653022
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 03/25/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653024
Principal investigator 1 Boehringer Ingelheim International GmbH $8.88 03/25/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653026
Principal investigator 1 Boehringer Ingelheim International GmbH $3.20 03/25/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653028
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653056
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 03/01/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220652998
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 03/01/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220653000
Principal investigator 1 United Therapeutics Corporation $1,728.00 02/26/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390759
Principal investigator 1 United Therapeutics Corporation $7,681.50 02/26/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390765
Principal investigator 1 United Therapeutics Corporation $1,728.00 02/26/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390863
Principal investigator 1 United Therapeutics Corporation $9,066.60 02/26/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390869
Principal investigator 1 United Therapeutics Corporation $2,232.90 02/12/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390865
Principal investigator 1 United Therapeutics Corporation $2,851.20 02/12/2025 Non-covered Recipient Entity
University of Cincinnati Physicians Company, LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390867
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,860.00 02/03/2025 Non-covered Recipient Entity
University Of Cincinnati
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220794407
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220652994
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220652996
Principal investigator 1 United Therapeutics Corporation $1,998.00 01/29/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390761
Principal investigator 1 United Therapeutics Corporation $2,851.20 01/29/2025 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390763
Principal investigator 1 United Therapeutics Corporation $2,925.45 01/29/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390819
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653002
Principal investigator 1 Boehringer Ingelheim International GmbH $14.02 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653004
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653006
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653008
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653010
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653012
Principal investigator 1 Boehringer Ingelheim International GmbH $1.60 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220653014
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653046
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653048
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653050
Principal investigator 1 Boehringer Ingelheim International GmbH $6.72 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653052
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 01/27/2025 Non-covered Recipient Entity
University Of Cincinnati
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220653054
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,748.10 01/21/2025 Non-covered Recipient Entity
University of Cincinnati
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806975
Principal investigator 1 United Therapeutics Corporation $2,419.20 01/03/2025 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390817
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220652990
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220652992